One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to address that disease,” Colin Murdoch, Isomorphic Labs president and Google DeepMind's chief business officer said.

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 million.

Out to make a bigger difference, Alphabet’s Isomorphic Labs is exploring a much more useful application of AI. The Google DeepMind subsidiary is set to begin human trials for AI-designed drugs, marking a big step forward for the medical industry.

Google DeepMind's drug discovery company, Isomorphic Labs, is gearing up to launch the human trials of its AI-designed drugs.

Google DeepMind's Isomorphic Labs is preparing for human trials of AI-designed drugs, marking a significant advancement in pharmaceutical innovation.

Google DeepMind is getting ready to begin human testing of drugs developed using artificial intelligence. All you need to know

Isomorphic Labs advances towards human clinical trials for AI-designed drugs, marking a pivotal moment in pharmaceutical research.

One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to address that disease,” Colin Murdoch, Isomorphic Labs president and Google DeepMind's chief business officer said.